Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche Completes $2.7B Acquisition of Carmot Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Roche Completes $2.7B Acquisition of Carmot Therapeutics

Gains R&D portfolio of therapeutics for metabolic diseases including diabetes and obesity.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche has completed its acquisition of Carmot Therapeutics, a clinical-stage biotechnology company developing therapeutics for metabolic diseases, for $2.7 billion and as much as $400 million based on the achievement of certain milestones.

Roche obtains access to Carmot’s current R&D portfolio including all clinical and preclinical assets, as well as exclusive access to Carmot’s Chemotype Evolution discovery platform in metabolism. Carmot and its employees will join the Roche Group as part of Roche’s Pharmaceuticals Division.

Carmot’s portfolio of incretins include: lead asset CT-388, a Phase-2 ready, dual GLP-1/GIP receptor agonist for the treatment of obesity in patients with and without type 2 diabetes; CT-996, a once-daily oral, small molecule GLP-1 receptor agonist currently in Phase-1 intended to treat obesity in patients with and without type 2 diabetes; and CT-868, a Phase-2, once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist intended for the treatment of type 1 diabetes patients with overweight or obesity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters